590 material Form 8-K filings that 521 companies we cover made with the SEC in October 2024, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
WD-40 reported fourth-quarter fiscal 2024 net sales of $156.0 million, up 11%, and diluted EPS of $1.23 versus $1.21 a year earlier. It also issued fiscal 2025 guidance on a pro forma basis that excludes homecare and cleaning brands it expects to divest, and said it expects that divestiture to close in the first half of fiscal 2025.
Q4 net sales $156.0 million, up 11%; net income $16.8 million, up 1%; diluted EPS $1.23 vs. $1.21
Fiscal 2024 net sales $590.6 million, up 10%; net income $69.6 million; diluted EPS $5.11 vs. $4.83
FY2025 guidance: net sales $600 million to $630 million on a constant currency basis; operating income $95 million to $100 million; diluted EPS $5.20 to $5.45
Board declared a $0.88 per share quarterly dividend payable October 31, 2024 to holders of record on October 18, 2024
KeyCorp reported a third-quarter 2024 net loss from continuing operations attributable to common shareholders of $447 million, or $0.47 per diluted share, after $737 million in after-tax charges tied to a securities portfolio repositioning. Excluding those charges, adjusted net income was $290 million, or $0.30 per diluted share, up from $237 million, or $0.25, in the second quarter, though total revenue fell to $695 million from $1.5 billion. The company received an initial $821 million tranche of its Scotiabank strategic investment, and expects the final tranche in the first quarter of 2025, subject to Federal Reserve approval.
Net loss of $447 million, or $0.47 per diluted share, versus net income of $266 million in the third quarter of 2023
Adjusted net income of $290 million, or $0.30 per diluted share, excluding $737 million in after-tax charges
Net interest income rose 7% quarter-over-quarter to $964 million; total revenue (TE) was $695 million versus $1,526 million in the second quarter
Received initial $821 million Scotiabank investment tranche; Common Equity Tier 1 ratio was 10.8%
Marsh McLennan reported third-quarter 2024 results with revenue of $5.7 billion, up 6%, and GAAP diluted EPS of $1.51, up 3%, with adjusted EPS of $1.63, up 4%. The company also disclosed a September 29, 2024 agreement to acquire McGriff Insurance Services for $7.75 billion in cash, targeted to close by year-end, subject to regulatory clearance.
Q3 2024 GAAP revenue $5.7 billion, up 6%; underlying revenue up 5%
Q3 GAAP net income attributable to the Company $747 million; GAAP diluted EPS $1.51, up 3%
Nine-month GAAP diluted EPS $6.59, up 10%; adjusted EPS $6.93, up 10%
McGriff acquisition: $7.75 billion cash consideration, targeted to close by year-end 2024
Elevance Health reported third quarter 2024 operating revenue of $44.7 billion, up 5.3% from a year earlier, but GAAP diluted EPS fell 20.0% to $4.36 and the operating gain fell 19.8% to $1.4 billion. The company cited a timing mismatch between Medicaid rates and the higher acuity of its members, which pushed the benefit expense ratio up 270 basis points to 89.5%. It now expects 2024 GAAP EPS of approximately $26.50 and adjusted EPS of approximately $33.00, and on October 15, 2024 it authorized an $8.0 billion increase to its share repurchase program.
Q3 2024 operating revenue $44.7 billion, up $2.2 billion from the prior year quarter, driven by higher premium yields and CarelonRx product revenue
Q3 2024 GAAP diluted EPS $4.36 versus $5.45 a year earlier; adjusted diluted EPS $8.37 versus $8.99
Medical membership fell 3.3% year over year to 45,760 thousand, with Medicaid down 19.0% to 8,926 thousand
Board authorized an $8.0 billion increase to the share repurchase program on October 15, 2024; quarterly dividend of $1.63 per share declared
Texas Capital Bancshares reported a net loss available to common stockholders of $65.6 million, or $1.41 per diluted share, for the quarter ended September 30, 2024, compared with net income of $37.4 million, or $0.80 per diluted share, in the second quarter. The loss was driven mainly by a $179.6 million loss on the sale of available-for-sale debt securities, which matters to shareholders because it erased the prior quarter's profit and reduced stockholders' equity.
Net loss available to common stockholders of $65.6 million, or $1.41 per diluted share, versus net income of $37.4 million, or $0.80, in Q2 2024
$179.6 million loss on sale of available-for-sale debt securities ($2.92 per diluted share) and $5.9 million in restructuring expense
Net interest income rose to $240.1 million from $216.6 million in Q2 2024; net interest margin was 3.16%
Book value per share was $66.09 at September 30, 2024, up 14% year over year
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.